Michael Gelband’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Michael Gelband’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,293	Closed	-$579K	–	2174
2023 Q3	$579K	Sell	13,293 -85,445	-87%	-$3.05M	0.01%	1186
2023 Q2	$3.57M	Sell	98,738 -65,004	-40%	-$2.68M	0.03%	575
2023 Q1	$6.09M	Buy	163,742 +144,328	+743%	+$6.49M	0.05%	443
2022 Q4	$880K	Sell	19,414 -19,988	-51%	-$1.29M	0.01%	993
2022 Q3	$2.75M	Buy	+39,402	New	+$2.92M	0.04%	635
2022 Q2	–	Sell	-38,927	Closed	-$3.2M	–	2598
2022 Q1	$3.2M	Buy	38,927 +20,046	+106%	+$2.05M	0.04%	566
2021 Q4	$2.77M	Buy	+18,881	New	+$2.93M	0.03%	631
2021 Q3	–	Sell	-25,713	Closed	-$4.15M	–	2796
2021 Q2	$4.15M	Buy	25,713 +17,811	+225%	+$2.86M	0.05%	417
2021 Q1	$1.35M	Sell	7,902 -391	-5%	-$77.4K	0.02%	747
2020 Q4	$1.82M	Buy	+8,293	New	+$1.79M	0.02%	577
2020 Q2	–	Sell	-23,854	Closed	-$1.83M	–	2094
2020 Q1	$1.83M	Buy	+23,854	New	+$2.14M	0.1%	197

Other funds holding MRTX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Michael Gelband's MRTX Position: Q4 2023 in Review

Michael Gelband sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 13,293 shares — an estimated $579K sold.

Michael Gelband first reported a position in MRTX in Q1 2020 and held it in 11 quarters. The position peaked at $6.09M in Q1 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Michael Gelband reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Michael Gelband sold 13,293 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $579K.
Michael Gelband first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
Michael Gelband's Mirati Therapeutics, Inc. Common Stock position peaked at $6.09M in Q1 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.